Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully placed a note loan with a volume of 750 million euros. The note loan was issued with maturity terms of 3, 5, 7 and 10 years and was significantly oversubscribed. “We see such great interest as clear proof of our attractiveness for investors,” said Rainer Lehmann, Chief Financial Officer of Sartorius.
In view of high demand, the targeted minimum volume of 300 million euros was significantly exceeded. Most of the funds will be used for early repayment of the bridge loan that Sartorius had taken out at the end of April in connection with the acquisition of selected life science businesses from Danaher.
La mejor actitud que podemos adoptar es la de trat...
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Curapath se complace en reconocer el importante avance logrado por Mac...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory
